ZINC00640089

Research use only, not for human use.

ZINC00640089 is a selective lipid carrier protein-2 (LCN2) inhibitor. ZINC00640089 inhibited cell proliferation and cell viability, and reduced AKT phosphorylation in SUM149 cells. ZINC00640089 can be used to study inflammatory breast cancer (IBC).

ZINC00640089 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00640089 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. ZINC00640089 has good potential for research in inflammatory breast cancer (IBC).

ZINC00640089 (0.01-100 μM; 72 h) reduces cell proliferation and cell viability in SUM149 cells.ZINC00640089 (1, 10 μM; 15 min, 1 h) reduces the p-Akt levels in SUM149 cells.Cell Viability Assay Cell Line:SUM149 cells Concentration:0.01-100 μM Incubation Time:72 h Result:Reduced cell viability at concentrations of 1 μM or lower.Western Blot Analysis Cell Line:SUM149 cells Concentration:1, 10 μM Incubation Time:15 min, 1 h, 24 h Result:Reduced the p-Akt protein levels 15 min and 1 h and changes in the p-Akt protein levels were not observed at 24 h.

——

——

Cytoskeleton/Cell Adhesion Molecules

Akt

Akt

——

——

667880-11-7

370.32

C20H13F3N2O2

>98% (HPLC)

In Vitro:?DMSO : 12.5 mg/mL (33.75 mM; Ultrasonic (<60°C)

C(C(NC1=C(C(F)(F)F)C=CC=C1)=O)N2C=3C4=C(C2=O)C=CC=C4C=CC3

——

(-20℃)

With Ice Pack

≥ 2 years